Anixa Biosciences Inc — Investor Relations & Filings
Filings indexed
958
across all filing types
Latest filing
1996-06-14
Major Shareholding Noti…
Country
US
United States of America
Listing
US
ANIX
Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| AMEND NO. 4 TO SCHEDULE 13D | 1996-06-14 | English | |
| COPYTELE SECOND QUARTER 10-Q | 1996-06-13 | English | |
| AMEND NO. 3 TO SCHEDULE 13D/A | 1996-04-24 | English | |
| FORM 8-K | 1996-04-22 | English | |
| FIRST QUARTER 10-Q | 1996-03-14 | English | |
| COPYTELE FORM 10-K FOR PERIOD ENDING 10/31/95 | 1996-01-29 | English |
Browse filings by year
32 years- 2026 13 filings
- 2025 32 filings
- 2024 30 filings
- 2023 20 filings
- 2022 36 filings
- 2021 48 filings
- 2020 36 filings
- 2019 39 filings
- 2018 41 filings
- 2017 66 filings
- 2016 46 filings
- 2015 126 filings
- 2014 79 filings
- 2013 50 filings
- 2012 43 filings
- 2011 25 filings
- 2010 32 filings
- 2009 16 filings
- 2008 15 filings
- 2007 21 filings
- 2006 19 filings
- 2005 23 filings
- 2004 27 filings
- 2003 14 filings
- 2002 7 filings
- 2001 9 filings
- 2000 6 filings
- 1999 8 filings
- 1998 5 filings
- 1997 7 filings
- 1996 12 filings
- 1995 7 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
1996
6 filings
| |||||
| 9370281 | AMEND NO. 4 TO SCHEDULE 13D | 1996-06-14 | English | ||
| 9370282 | COPYTELE SECOND QUARTER 10-Q | 1996-06-13 | English | ||
| 9370283 | AMEND NO. 3 TO SCHEDULE 13D/A | 1996-04-24 | English | ||
| 9370284 | FORM 8-K | 1996-04-22 | English | ||
| 9370285 | FIRST QUARTER 10-Q | 1996-03-14 | English | ||
| 9370286 | COPYTELE FORM 10-K FOR PERIOD ENDING 10/31/95 | 1996-01-29 | English | ||
|
1995
7 filings
| |||||
| 9370287 | 10Q FOR PERIOD END 07/31/95 | 1995-09-12 | English | ||
| 9370289 | PROSPECTUS SUPPLEMENT | 1995-09-06 | English | ||
| 9370288 | COPYTELE INC 1993 STOCK OPTION PLAN | 1995-09-06 | English | ||
| 9370290 | AMEND NO. 2 TO SCH 13D | 1995-06-30 | English | ||
| 9370291 | AMEND NO. 3 TO SCHEDULE 13D | 1995-06-27 | English | ||
| 9370292 | NOTICE OF ANNUAL MEETING AND PROXY STATEMENT | 1995-06-14 | English | ||
| 9370293 | 10Q FOR PERIOD END 04/30/95 | 1995-06-09 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Anixa Biosciences Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34117/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34117 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34117 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34117 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34117}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Anixa Biosciences Inc (id: 34117)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.